AV 203

Drug Profile

AV 203

Alternative Names: AV-203; CAN-017

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVEO Pharmaceuticals
  • Developer AVEO Oncology; CANbridge Life Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Oesophageal cancer
  • No development reported Solid tumours

Most Recent Events

  • 21 Dec 2017 CANbridge Life Sciences submits an IND application to the China Food and Drug Administration for a phase Ib/III trial in Oesophageal squamous cell cancer
  • 21 Dec 2017 CANbridge Life Sciences plans a phase Ib/III trial in Oesophageal squamous cell cancer in China
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top